Genzyme Corporation And Isis Pharmaceuticals, Inc.'s Mipomersen Phase 3 Study in HoFH Patients Featured in The L

ClinicaSpace Login

Enter your ClinicaSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

Clinical Research
News & Careers

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
FREE Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Date
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Today's Hot Jobs
Most Recent Jobs
Search Jobs
Post Resume
Career Resources
For Employers

COMMUNITY
Login
Become a Member
FAQ

PROFILES
Company Profiles

INDUSTRY EVENTS
Clinical

RESOURCES
Real Estate
New Business Opportunities

News | News By Subject | News By Date | Search News

Email

Genzyme Corporation (GENZ) And Isis Pharmaceuticals, Inc. (ISIS)'s Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet
3/15/2010

CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Isis Pharmaceuticals, Inc.

• Genzyme Corporation

• Clinical - Phase III